Harmane and harmalan are bioactive components of classical clonidine-displacing substance

Biochemistry

Volumn 43, Issue 51, 2004, Pages 16385-16392

  Parker, Christine A ^a   Anderson, Neil J ^a   Robinson, Emma S J ^a   Price, Rhiannon ^a   Tyacke, Robin J ^a   Husbands, Stephen M ^b   Dillon, Michael P ^c   Eglen, Richard M ^c   Hudson, Alan L ^a   Nutt, David J ^a   Crump, Matthew P ^a,d   Crosby, John ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b University of Bath   (United Kingdom)

^c ROCHE BIOSCIENCE   (United States)

^d UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HIGH PRESSURE LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; NUCLEAR MAGNETIC RESONANCE;

CLONIDINE-DISPLACING SUBSTANCE (CDS); ELECTROSPRAY MASS SPECTROMETRY (ESMS); HARMALAN; HARMANE;

BIOLOGICAL MEMBRANES;

ALPHA 2 ADRENERGIC RECEPTOR; BETA CARBOLINE DERIVATIVE; CLONIDINE; HARMALAN; HARMAN; IMIDAZOLINE; LIGAND; TRYPTOPHAN; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; BINDING SITE; BRAIN MEMBRANE; ELECTROSPRAY MASS SPECTROMETRY; KIDNEY; LIGAND BINDING; LUNG; MALE; NONHUMAN; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; RAT; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY;

ANIMALS; CARBOLINES; CATTLE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CLONIDINE; HARMINE; LUNG; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION;

ANIMALIA; BOVINAE;

EID: 19944410141     PISSN: 00062960     EISSN: None     Source Type: Journal    
DOI: 10.1021/bi048584v     Document Type: Article

References (70)

1. Stahle, H., and Pook, K.-H. (1971) Synthases in der 2-amino-imidazolin- reihe, Liebigs Ann. Chem. 751, 159-167.
2. Yu, A., and Frishman, W. H. (1996) Imidazoline receptor agonist drugs: A new approach to the treatment of systemic hypertension, J. Clin. Pharmacol. 36, 98-111.
3. Kobinger, W. (1978) Central α-adrenergic systems as targets for hypotensive drugs, Rev. Physiol., Biochem. Pharmacol. 81, 40-100.
4. Eglen, R. M., Hudson, A. L., Kendall, D. A., Nutt, D. J., Morgan, N. G., Wilson, V. G., and Dillon, M. P. (1998) "seeing through a glass darkly": Casting light on imidazoline "I" sites, Trends Pharmacol. Sci. 19, 381-390.
5. Molderings, G. J., and Gothert, M. (1999) Imidazoline binding sites and receptors in cardiovascular tissue, Gen. Pharmacol. 32, 17-22.
6. Parini, A., Moudanos, C. G., Pizzinat, N., and Lanier, S. M. (1996) The elusive family of imidazoline binding sites, Trends Pharmacol. Sci 17, 13-16.
7. Reynolds, G. P., Boulton, R. M., Pearson, S. J., Hudson, A. L., and Nutt, D. J. (1996) Imidazoline binding sites in Huntington's and Parkinson's disease putamen, Eur. J. Pharmacol. 301, R19-R21.
8. Sastre, M., Ventayol, P., and GarciaSevilla, J. A. (1996) Decreased density of 1-2-imidazoline receptors in the postmortem brains of heroin addicts, Neuroreport 7, 509-512.
9. GarciaSevilla, J. A., Escriba, P. V., Sastre, M., Walzer, C., Busquets, X., Jaquet, G., Reis, D. J., and Guimon, J. (1996) Immunodetection and quantitation of imidazoline receptor proteins in platelets of patients with major depression and in brains of suicide victims, Arch. Gen. Psychiatry 53, 803-810.
10. Chan, S. L. F. (1998) Clonidine-displacing substance and its putative role in control of insulin secretion: a minireview, Gen. Pharmacol. 31, 525-529.
11. Atlas, D., and Burstein, Y. (1984) Isolation and partial-purification of a clonidine-displacing endogenous brain substance, Eur. J. Biochem. 144, 287-293.
12. Atlas, D. (1991) Clonidine-displacing substance (CDS) and its putative imidazoline receptor-new leads for further divergence of alpha-2-adrenergic receptor activity, Biochem. Pharmacol. 41, 1541-1549.
13. Regunathan, S., and Reis, D. J. (1996) Imidazoline receptors and their endogenous ligands, Annu. Rev. Pharmacol. Toxicol. 36, 511-544.
14. Atlas, D. (1994) Identifying clonidine-displacing substance, Science 266, 462-463.
15. Meeley, M. P., Hensley, M. L., Ernsberger, P., Felsen, D., and Reis, D. J. (1992) Evidence for a bioactive clonidine-displacing substance in peripheral-tissues and serum, Biochem. Pharmacol. 44, 733-740.
16. Li, G., Regunathan, S., Barrow, C. J., Eshraghi, J., Cooper, R., and Reis, D. J. (1994) Agmatine-an endogenous clonidine-displacing substance in the brain, Science 263, 966-969.
17. Bousquet, P., Feldman, J., and Atlas, D. (1986) An endogenous non-catecholamine clonidine antagonist increases mean arterial blood-pressure, J. Hypertens. 4, S569-S569.
18. Meeley, M. P., Ernsberger, P. R., Granata, A. R., and Reis, D. J. (1986) An endogenous clonidine-displacing substance from bovine brain-receptor-binding and hypotensive actions in the ventrolateral medulla, Life Sci. 38, 1119-1126.
19. Singh, G., Hussain, J. F., Mackinnon, A., Brown, C. M., Kendall, D. A., and Wilson, V. G. (1995) Evidence for the presence of a non-catecholamine, clonidine-displacing substance in crude, methanolic extracts of bovine brain and lung, Naunyn-Schmiedeberg's Arch. Pharmacol. 351, 17-26.
20. Parker, C. A., Hudson, A. L.. Nutt, D. J., Dillon, M. P., Eglen, R. M., Chan, S. L. F., Morgan, N. G., and Crosby, J. (1999) Extraction of active clonidine-displacing substance from bovine lung and comparison with clonidine-displacing substance extracted from other tissues, Eur. J. Pharmacol. 378, 213-221.
21. Parker, C. A., Hudson, A. L., Nutt, D. J., Dillon, M. P., Eglen, R. M., and Crosby, J. (2000) Isolation of RP-HPLC pure clonidine-displacing substance from NG108-15 cells, Eur. J. Pharmacol. 387, 27-30.
22. Susilo, R., and Rommelspacher, H. (1987) Formation of a beta-carboline (1,2,3,4-tetrahydro-1-methyl-beta-carboline-1-carboxylic acid) following intracerebroventricular injection of tryptamine and pyruvic-acid, Naunyn-Schmiedeberg's Arch. Pharmacol. 335, 70-76.
23. Brossi, A., Focella, A., and Teitel, S. (1973) Alkaloids in mammalian tissues. 3. Condensation of L-tryptophan and L-5-hydroxytryptophan with formaldehyde and acetaldehyde, J. Med. Chem. 16, 418-420.
24. Spath, E., and Lederer, E. (1930) Synthese der harmala-alkaloide: harmalin, harmin und harman, Berichte B 63, 120-125.
25. Parker, C. A., Hudson, A. L., Nutt, D. J., Dillon, M. P., Eglen, R. M., and Crosby, J. (1999) in Imidazoline receptors and their endogenous ligands, pp 92-96, New York Academy of Sciences, New York.
26. Tsuchiya, H., Sato, M., Hayashi, H., Kato, H., Kureshiro, H., and Hayashi, T. (1996) Simultaneous determination of tetrahydro-beta-carbolines and beta-carbolines, Chromatographia 43, 419-425.
27. Lione, L. A., Nutt, D. J., and Hudson, A. L. (1998) Characterisation and localisation of [H-3]2-(2-benzofuranyl)-2- imidazoline binding in rat brain: A selective ligand for imidazoline 1-2 receptors, Eur. J. Pharmacol. 353, 123-135.
28. Bradford, M. M. (1976) A rapid sensitive method for the quantification of protein using the principle of protein dye binding, Anal. Biochem. 72, 248-252.
29. Parker, C. A., Hudson, A. L., Nutt, D. J., Dillon, M. P., Eglen, R. M., and Crosby, J. (1999) Tryptophan: A distinct but biologically inactive component of clonidine-displacing substance, Br. J. Pharmacol. 127, 72P.
30. Husbands, S. M., Glennon, R. A., Gorgerat, S., Cough, R., Tyacke, R., Crosby, J., Nutt, D. J., Lewis, J. W., and Hudson, A. L. (2001) Beta-carboline binding to imidazoline receptors, Drug Alcohol Depend. 64, 203-208.
31. Ernsberger, P., Graves, M. E., Graff, L. M., Zakieh, N., Nguyen, P., Collins, L. A., Westbrooks, K. L., and Johnson, G. G. (1995) II-imidazoline receptors. Definition, characterisation, distribution and transmembrane signaling, Ann. N. Y. Acad. Sci. 763, 22-43.
32. Herbert, R. B., and Mann, J. (1982) The biosynthesis of the beta-carboline alkaloids, harman and eleagnine, J. Chem. Soc., Perkin Trans. I, 1523-1525.
33. McKenna, D. J., and Towers, G. H. N. (1984) Biochemistry and pharmacology of tryptamines and beta- carbolines-a minireview, J. Psychoact. Drugs 16, 347-358.
34. Goldbergstern, H., Atlas, D., Schwartz, L., Achiron, A., Ziv, I., Djaldetti, R., Zoldan, Y., and Melamed, E. (1993) Detection and measurement of an endogenous clonidine-displacing substance in human cerebrospinal-fluid, Brain Res. 601, 325-328.
35. Kreisberg, G. A., Diamant, S., Diamant, Y. Z., and Atlas, D. (1987) Serum and placenta! clonidine displacing substance (CDS) in hypertensive pregnancy, Clin. Exp. Hypertens. B 6, 147-147.
36. Felsen, D., Ernsberger, P., Meeley, M. P., and Reis, D. J. (1987) Clonidine displacing substance is biologically-active on smooth-muscle, Eur. J. Pharmacol. 142, 453-455.
37. Regunathan, S., Meeley, M. P., and Reis, D. J. (1991) Clonidine-displacing substance from bovine brain binds to imidazoline receptors and releases catecholamines in adrenal chromaffin cells, Mol. Pharmacol. 40, 884-888.
38. Dontenwill, M., Bricca, G., Molines, A., Belcourt, A., and Bousquet, P. (1987) A polyclonal antibody raised against clonidine-a model for the specific imidazoline receptor, Eur. J. Pharmacol. 137, 143-144.
39. Meeley, M. P., Towle, A. C., Ernsberger, P., and Reis, D. J. (1988) A specific antiserum recognizes clonidine-displacing substance-implications for the structure of the brains own clonidine, Neurosci. Lett. 84, 84-90.
40. Grigg, M., Musgrave, I. F., and Barrow, C. J. (1998) Isolation and partial structure determination of a clonidine-displacing substance from bovine lung and brain, J. Anton. Nerv. Syst. 72, 86-93.
41. Raasch, W., Schafer, U., Qadri, F., and Dominiak, P. (2002) Agmatine, an endogenous ligand at imidazoline binding sites, does not antagonize the clonidine-mediated blood pressure reaction, Br. J. Pharmacol. 135, 663-672.
42. Philips, S. R., Durden, D. A., and Boulton, A. A. (1974) Identification and distribution of tryptamine in the rat, Can. J. Biochem. 52, 447-451.
43. Kellar, K. J., and Cascio, C. S. (1982) [H-3]-labeled tryptamine-high-affinity binding-sites in rat-brain, Eur. J. Pharmacol. 78, 475-478.
44. Bruning, G., and Rommelspacher, H. (1984) High-affinity tryptamine-H-3 binding-sites in various organs of the rat, Life Sci. 34, 1441-1446.
45. Durden, D. A., and Philips, S. R. (1980) Kinetic measurements of the turnover rates of phenylethylamine and tryptamine in vivo in the rat brain, J. Neurochem. 34, 1725-1732.
46. Musgrave, I. F., and Badoer, E. (2000) Harmane produces hypotension following microinjection into the RVLM: Possible role of I-1-imidazoline receptors, Br. J. Pharmacol. 129, 1057-1059.
47. Adell, A., Biggs, T. A., and Myers, R. D. (1996) Action of harman (1-methyl-beta-carboline) on the brain: body temperature and in vivo efflux of 5-HT from hippocampus of the rat, Neuropharmacology 35, 1101-1107.
48. Fekkes, D., and Bode, W. T. (1993) Occurrence and partition of the beta-carboline norharman in rat organs, Life Sci. 52, 2045-2054.
49. Herraiz, T., and Papavergou, E. (2004) Identification and occurrence of tryptamine- and tryptophan-derived tetrahydro-beta-carbolines in commercial sausages, J. Agric. Food Chem. 52, 2652-2658.
50. Herraiz, T., and Galisteo, J. (2003) Tetrahydro-beta-carboline alkaloids occur in fruits and fruit juices. Activity as antioxidants and radical scavengers, J. Agric. Food Chem. 51, 7156-7161.
51. Steidlova, S., and Kalac, P. (2002) Levels of biogenic amines in maize silages, Anim. Feed Sci. Technol. 102, 197-205.
52. Fekkes, D., Tuiten, A., Bom, I., and Pepplinkhuizen, L. (2001) Pharmacokinetics of the beta-carboline norharman in man, Life Sci. 69, 2113-2121.
53. Rommelspacher, H., Bruning, G., Susilo, R., Nick, M., and Hill, R. (1985) Pharmacology of harmalan (1-methyl-3,4-dihydro-beta-carboline), Eur. J. Pharmacol. 109, 363-371.
54. Susilo, R., Damm, H., Rommelspacher, H., and Hofle, G. (1987) Biotransformation of 1-methyl-1,2,3,4-tetrahydro-beta-carboline-1-carboxylic acid to harmalan, tetrahydroharman and harman in rats, Neurosci. Lett. 81, 325-330.
55. Naoi, M., Maruyama, W., Dostert, P., Kohda, K., and Kaiya, T. (1996) A novel enzyme enantioselectively synthesizes (R-)-salsolinol, a precursor of a dopaminergic neurotoxin, N-methyl-(R-)salsolinol, Neurosci. Lett. 212, 183-186.
56. Reis, D. J., Regunathan, S., and Meeley, M. P. (1992) Imidazole receptors and clonidine-displacing substance in relationship to control of blood-pressure, neuroprotection, and adrenomedullary secretion, Am. J. Hypertens. 5, S51-S57.
57. Mizuno, Y., Mori, H., and Kondo, T. (1994) Potential of neuroprotective therapy in Parkinsons-disease, CNS Drugs 1, 45-56.
58. Collins, M. A., and Neafsey, E. J. (1985) Beta-carboline analogs of N-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP)-endogenous factors underlying idiopathic Parkinsonism, Neurosci. Lett. 55, 179-184.
59. Gearhart, D. A., Neafsey, E. J., and Collins, M. A. (2002) Phenylethanolarnine n-methyltransferase has beta-carboline 2N-methyltransferase activity: hypothetical relevance to Parkinson's disease, Neurochem. Int. 40, 611-620.
60. Rommelspacher, H., May, T., and Salewski, B. (1994) Harman (1-methyl-beta-carboline) is a natural inhibitor of monoamine-oxidase type-A in rats, Eur. J. Pharmacol. 252, 51-59.
61. Kim, H., Sablin, S. O., and Ramsay, R. R. (1997) Inhibition of monoamine oxidase a by beta-carboline derivatives, Arch. Biochem. Biophys. 337, 137-142.
62. Glennon, R. A., Dukat, M., Grella, B., Hong, S. S., Costantino, L., Teitler, M., Smith, C., Egan, C., Davis, K., and Mattson, M. V. (2000) Binding of beta-carbolines and related agents at serotonin (5-HT2 and 5-HT1a), dopamine (D-2) and benzodiazepine receptors, Drug Alcohol Depend. 60, 121-132.
63. Demeester, C. (1995) Genotoxic potential of beta-carbolines-a review, Mutat. Res. 339, 139-153.
64. Klinker, J. F., Seifert, R., Damm, H., and Rommelspacher, H. (1997) Activation by beta-carbolines of G-proteins in HL-60 membranes and the bovine retinal G-protein transducin in a receptor-independent manner, Biochem. Pharmacol. 53, 1621-1626.
65. Higashimoto, M., Yamamoto, T., Kinouchi, T., Matsumoto, H., and Ohnishi, Y. (1996) Mutagenicity of 1-methyl-1,2,3,4-tetrahydro-beta-carboline-3-carboxyl acid treated with nitrite in the presence of alcohols, Mutat. Res. 367, 43-49.
66. Totsuka, Y., Ushiyama, H., Ishihara, J., Sinha, R., Goto, S., Sugimura, T., and Wakabayashi, K. (1999) Quantification of the co-mutagenic beta-carbolines, norharman and harman, in cigarette smoke condensates and cooked foods, Cancer Lett. 143, 139-143.
67. Robinson, E. S. J., Price, R. E., Nutt, D. J., and Hudson, A. L. (2003) Agmatine and imidazolines: Their novel receptors and enzymes, Ann. N.Y. Acad. Sci. 1009, 157-166.
68. Glennon, R. A., Grella, B., Tyacke, R. J., Lau, A., Westaway, J., and Hudson, A. L. (2004) Binding of an imidazopyridoindole at imidazoline 1-2 receptors, Bioorg. Med. Chem. Lett. 14, 527-529.
69. Glennon, R. A., Grella, B., Tyacke, R. J., Lau, A., Westaway, J., and Hudson, A. L. (2004) Binding of beta-carbolines at imidazoline I-2 receptors: A structure-affinity investigation, Bioorg. Med. Chem. Lett. 14, 999-1002.
70. Chang-Fong, J., Tyacke, R. J., Lau, A., Westaway, J., Hudson, A. L., and Glennon, R. A. (2004) Pyrazino[1,2-a]indoles as novel high-affinity and selective imidazoline 1-2 receptor ligands, Bioorg. Med. Chem. Lett. 14, 1003-1005.